At a glance
ClinicalIndex Comparison RecordN/ACompleted· 13,980 enrolled
Drug / intervention
Edoxabandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation
In Brief
An observational study evaluating Edoxaban for Atrial Fibrillation. Completed, enrolled 13,980 participants across 724 sites in 10 countries.
Detailed Summary
In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the Non-valvular Atrial Fibrillation (NVAF) indication, Daiichi-Sankyo proposed this post-authorization safety study (PASS) to gain insight into the safety (bleeding, liver adverse events, all-cause mortality and other drug related adverse events) of edoxaban use in patients with NVAF who were not preselected.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesAustria, Belgium, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
First PostedOct 2016
Primary CompletionApr 2022
TodayJul 2026
First PostedOct 25, 2016
Enrollment StartAug 1, 2015
Primary CompletionApr 13, 2022
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 9.7 years ago
Interventions
Edoxabandrug
Prescribed according to approved label